These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 34427065)

  • 1. Effectiveness of Convalescent Plasma Therapy in Severe or Critically Ill COVID-19 Patients: A Retrospective Cohort Study.
    Cho Y; Sohn Y; Hyun J; Baek Y; Kim M; Kim J; Ahn J; Jeong S; Ku N; Yeom JS; Ahn M; Oh D; Choi J; Kim S; Lee K; Song Y; Choi J
    Yonsei Med J; 2021 Sep; 62(9):799-805. PubMed ID: 34427065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.
    Keitel V; Jensen B; Feldt T; Fischer JC; Bode JG; Matuschek C; Bölke E; Budach W; Plettenberg C; Scheckenbach K; Kindgen-Milles D; Timm J; Müller L; Kolbe H; Stöhr A; Calles C; Hippe A; Verde P; Spinner CD; Schneider J; Wolf T; Kern WV; Nattermann J; Zoufaly A; Ohmann C; Luedde T;
    Trials; 2021 May; 22(1):343. PubMed ID: 34001215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma.
    Shen C; Wang Z; Zhao F; Yang Y; Li J; Yuan J; Wang F; Li D; Yang M; Xing L; Wei J; Xiao H; Yang Y; Qu J; Qing L; Chen L; Xu Z; Peng L; Li Y; Zheng H; Chen F; Huang K; Jiang Y; Liu D; Zhang Z; Liu Y; Liu L
    JAMA; 2020 Apr; 323(16):1582-1589. PubMed ID: 32219428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Convalescent plasma transfusion therapy in severe COVID-19 patients- a safety, efficacy and dose response study: A structured summary of a study protocol of a phase II randomized controlled trial.
    Chowdhury FR; Hoque A; Chowdhury FUH; Amin MR; Rahim A; Rahman MM; Yasmin R; Amin MR; Miah MT; Kalam MA; Rahman MS
    Trials; 2020 Oct; 21(1):883. PubMed ID: 33106167
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Convalescent plasma therapy in critically İll COVID-19 patients: A retrospective cohort study.
    Sevdi MS; Erkalp K; Ozalp A; Ozcan FG; Demirgan S; Akyol O; Guneyli HC; Tunali MC; Selcan A
    Niger J Clin Pract; 2023 Oct; 26(10):1410-1422. PubMed ID: 37929515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjunctive treatment with high-titre convalescent plasma in severely and critically ill COVID-19 patients - a safe but futile intervention. A comparative cohort study.
    Hoepler WP; Weidner L; Traugott MT; Neuhold S; Meyer EL; Zoufaly A; Seitz T; Kitzberger R; Baumgartner S; Pawelka E; Karolyi M; Grieb A; Hind J; Laferl H; Friese E; Wenisch C; Aberle SW; Aberle JH; Weseslindtner L; Jungbauer C
    Infect Dis (Lond); 2021 Nov; 53(11):820-829. PubMed ID: 34128763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Efficacy of Convalescent Plasma Use in Critically Ill COVID-19 Patients.
    Tirnea L; Bratosin F; Vidican I; Cerbu B; Turaiche M; Timircan M; Margan MM; Marincu I
    Medicina (Kaunas); 2021 Mar; 57(3):. PubMed ID: 33799535
    [No Abstract]   [Full Text] [Related]  

  • 8. Lessons learned from early compassionate use of convalescent plasma on critically ill patients with Covid-19.
    Liu M; Chen Z; Dai MY; Yang JH; Chen XB; Chen D; You H; Guo X; Leng Y; Yu L; Zhang ML; Wu X; Yang J; Gao C; Tenen DG; Chai L; Ai F
    Transfusion; 2020 Oct; 60(10):2210-2216. PubMed ID: 32770691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review.
    Valk SJ; Piechotta V; Chai KL; Doree C; Monsef I; Wood EM; Lamikanra A; Kimber C; McQuilten Z; So-Osman C; Estcourt LJ; Skoetz N
    Cochrane Database Syst Rev; 2020 May; 5(5):CD013600. PubMed ID: 32406927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Convalescent plasma therapy in patients with COVID-19.
    Altuntas F; Ata N; Yigenoglu TN; Bascı S; Dal MS; Korkmaz S; Namdaroglu S; Basturk A; Hacıbekiroglu T; Dogu MH; Berber İ; Dal K; Kınık K; Haznedaroglu İ; Yılmaz FM; Kılıç İ; Demircioğlu S; Yosunkaya A; Erkurt MA; Turgut B; Caglayan M; Celik O
    Transfus Apher Sci; 2021 Feb; 60(1):102955. PubMed ID: 33011076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Convalescent plasma therapy in patients with severe COVID-19, A single-arm, retrospective study.
    Ghadami L; Hasibi M; Asadollahi-Amin A; Asanjarani B; Farahmand M; Abdollahi H
    Microb Pathog; 2022 Apr; 165():105482. PubMed ID: 35288278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized clinical trial to evaluate safety and efficacy of convalescent plasma use among hospitalized patients with COVID-19 (PERUCONPLASMA): a structured summary of a study protocol for a randomized controlled trial.
    Soto A; Krapp F; Vargas A; Cabrejos L; Argumanis E; García PL; Altamirano K; Montes M; Chacón-Uscamaita PR; García PJ
    Trials; 2021 May; 22(1):342. PubMed ID: 34001174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transfusion reactions associated with COVID-19 convalescent plasma therapy for SARS-CoV-2.
    Nguyen FT; van den Akker T; Lally K; Lam H; Lenskaya V; Liu STH; Bouvier NM; Aberg JA; Rodriguez D; Krammer F; Strauss D; Shaz BH; Rudon L; Galdon P; Jhang JS; Arinsburg SA; Baine I;
    Transfusion; 2021 Jan; 61(1):78-93. PubMed ID: 33125158
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Convalescent Plasma Therapy on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Profile in Coronavirus Disease 2019 (COVID-19) Patients.
    Tang J; Grubbs G; Lee Y; Golding H; Khurana S
    Clin Infect Dis; 2022 Jan; 74(2):327-334. PubMed ID: 33861337
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Antibody Titers in Convalescent Plasma and Recipients in New Mexico: An Open Treatment Study in Patients With Coronavirus Disease 2019.
    Bradfute SB; Hurwitz I; Yingling AV; Ye C; Cheng Q; Noonan TP; Raval JS; Sosa NR; Mertz GJ; Perkins DJ; Harkins MS
    J Infect Dis; 2020 Oct; 222(10):1620-1628. PubMed ID: 32779705
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial.
    Eckhardt CM; Cummings MJ; Rajagopalan KN; Borden S; Bitan ZC; Wolf A; Kantor A; Briese T; Meyer BJ; Jacobson SD; Scotto D; Mishra N; Philip NM; Stotler BA; Schwartz J; Shaz B; Spitalnik SL; Eisenberger A; Hod EA; Justman J; Cheung K; Lipkin WI; O'Donnell MR
    Trials; 2020 Jun; 21(1):499. PubMed ID: 32513308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Convalescent Plasma on Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial.
    ; Estcourt LJ; Turgeon AF; McQuilten ZK; McVerry BJ; Al-Beidh F; Annane D; Arabi YM; Arnold DM; Beane A; Bégin P; van Bentum-Puijk W; Berry LR; Bhimani Z; Birchall JE; Bonten MJM; Bradbury CA; Brunkhorst FM; Buxton M; Callum JL; Chassé M; Cheng AC; Cove ME; Daly J; Derde L; Detry MA; De Jong M; Evans A; Fergusson DA; Fish M; Fitzgerald M; Foley C; Goossens H; Gordon AC; Gosbell IB; Green C; Haniffa R; Harvala H; Higgins AM; Hills TE; Hoad VC; Horvat C; Huang DT; Hudson CL; Ichihara N; Laing E; Lamikanra AA; Lamontagne F; Lawler PR; Linstrum K; Litton E; Lorenzi E; MacLennan S; Marshall J; McAuley DF; McDyer JF; McGlothlin A; McGuinness S; Miflin G; Montgomery S; Mouncey PR; Murthy S; Nichol A; Parke R; Parker JC; Priddee N; Purcell DFJ; Reyes LF; Richardson P; Robitaille N; Rowan KM; Rynne J; Saito H; Santos M; Saunders CT; Serpa Neto A; Seymour CW; Silversides JA; Tinmouth AA; Triulzi DJ; Turner AM; van de Veerdonk F; Walsh TS; Wood EM; Berry S; Lewis RJ; Menon DK; McArthur C; Zarychanski R; Angus DC; Webb SA; Roberts DJ; Shankar-Hari M
    JAMA; 2021 Nov; 326(17):1690-1702. PubMed ID: 34606578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical characteristics and plasma antibody titer of patients with COVID-19 in Zhejiang, China.
    Xiang WL; Cheng JJ; Wu LP; Chen BY; Li WX; Qiu DY; Zhang W; Ge FH; Chen D; Wang Z
    J Zhejiang Univ Sci B; 2020 Dec.; 21(12):955-960. PubMed ID: 33843161
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Convalescent plasma is of limited clinical benefit in critically ill patients with coronavirus disease-2019: a cohort study.
    Huang L; Zhang C; Zhou X; Zhao Z; Wang W; Leng W; Su X; Lian Q
    J Transl Med; 2021 Aug; 19(1):365. PubMed ID: 34446049
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of convalescent plasma for severe COVID-19: a randomized, single blinded, parallel, controlled clinical study.
    Rojas M; Rodríguez Y; Hernández JC; Díaz-Coronado JC; Vergara JAD; Vélez VP; Mancilla JP; Araujo I; Yepes JT; Ricaurte OB; Pardo-Oviedo JM; Monsalve DM; Acosta-Ampudia Y; Ramírez-Santana C; García PG; Landinez LA; Correales LD; Grass JS; Pérez CR; López GS; Mateus N; Mancera L; Devia RR; Orjuela JE; Parra-Moreno CR; Buitrago AA; Ordoñez IE; Osorio CF; Ballesteros N; Patiño LH; Castañeda S; Muñoz M; Ramírez JD; Bastard P; Gervais A; Bizien L; Casanova JL; Camacho B; Gallo JE; Gómez O; Rojas-Villarraga A; Pérez CE; Manrique R; Mantilla RD; Anaya JM
    BMC Infect Dis; 2022 Jun; 22(1):575. PubMed ID: 35761219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.